Literature DB >> 19552661

Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria.

Joep J G van Oosterhout1, Lillian Brown, Ralf Weigel, Johnstone J Kumwenda, Dalitso Mzinganjira, Nasinuku Saukila, Brian Mhango, Thomas Hartung, Sam Phiri, Mina C Hosseinipour.   

Abstract

OBJECTIVES: In antiretroviral therapy (ART) scale-up programmes in sub-Saharan Africa viral load monitoring is not recommended. We wanted to study the impact of only using clinical and immunological monitoring on the diagnosis of virological ART failure under routine circumstances.
METHODS: Clinicians in two urban ART clinics in Malawi used clinical and immunological monitoring to identify adult patients for switching to second-line ART. If patients met clinical and/or immunological failure criteria of WHO guidelines and had a viral load <400 copies/ml there was misclassification of virological ART failure.
RESULTS: Between January 2006 and July 2007, we identified 155 patients with WHO criteria for immunological and/or clinical failure. Virological ART failure had been misclassified in 66 (43%) patients. Misclassification was significantly higher in patients meeting clinical failure criteria (57%) than in those with immunological criteria (30%). On multivariate analysis, misclassification was associated with being on ART <2 years [OR = 7.42 (2.63, 20.95)] and CD4 > 200 cells/microl [OR = 5.03 (2.05, 12.34)]. Active tuberculosis and Kaposi's sarcoma were the most common conditions causing misclassification of virological ART failure.
CONCLUSION: Misclassification of virological ART failure occurs frequently using WHO clinical and immunological criteria of ART failure for poor settings. A viral load test confirming virological ART failure is therefore advised to avoid unnecessary switching to second-line regimens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19552661     DOI: 10.1111/j.1365-3156.2009.02309.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  61 in total

1.  On the front line of HIV virological monitoring: barriers and facilitators from a provider perspective in resource-limited settings.

Authors:  S E Rutstein; C E Golin; S B Wheeler; D Kamwendo; M C Hosseinipour; M Weinberger; W C Miller; A K Biddle; A Soko; M Mkandawire; R Mwenda; A Sarr; S Gupta; R Mataya
Journal:  AIDS Care       Date:  2015-08-17

2.  Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children.

Authors:  Benjamin P Westley; Allison K DeLong; Chhraing S Tray; Dim Sophearin; Elizabeth M Dufort; Eric Nerrienet; Leeann Schreier; Joseph I Harwell; Rami Kantor
Journal:  Clin Infect Dis       Date:  2012-04-26       Impact factor: 9.079

3.  Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.

Authors:  Theodore D Ruel; Moses R Kamya; Pelin Li; William Pasutti; Edwin D Charlebois; Teri Liegler; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong; Jane Achan
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

4.  Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.

Authors:  M C Hosseinipour; J J Kumwenda; R Weigel; L B Brown; D Mzinganjira; B Mhango; J J Eron; S Phiri; J J van Oosterhout
Journal:  HIV Med       Date:  2010-03-19       Impact factor: 3.180

5.  [Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru].

Authors:  Jorge Alave; Jorge Paz; Elsa González; Miguel Campos; Martin Rodríguez; James Willig; Juan Echevarría
Journal:  Rev Chilena Infectol       Date:  2013-02       Impact factor: 0.520

6.  Regional differences in predictive accuracy of WHO immunologic failure criteria.

Authors:  Agnes N Kiragga; Barbara Castelnuovo; Moses R Kamya; Richard Moore; Yukari C Manabe
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

7.  Is CD4 monitoring needed among ugandan clients achieving a virologic and immunologic response to treatment?

Authors:  Steven J Reynolds; Joseph B Sempa; Agnes N Kiragga; Kevin Newell; Gertrude Nakigozi; Ronald Galiwango; Ron Gray; Thomas C Quinn; David Serwadda; Larry Chang
Journal:  AIDS Patient Care STDS       Date:  2014-10-07       Impact factor: 5.078

8.  Reply to 'Quantification of HIV-1 RNA on Dried Blood Spots' AIDS 24:475-6.

Authors:  Sarah M Lofgren; Wendy S Stevens; John A Bartlett; John A Crump
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

9.  Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.

Authors:  Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

10.  Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots.

Authors:  Susan C Aitken; Aletta Kliphuis; Michelle Bronze; Carole L Wallis; Cissy Kityo; Sheila Balinda; Wendy Stevens; Nicole Spieker; Tulio de Oliveira; Tobias F Rinke de Wit; Rob Schuurman
Journal:  J Clin Microbiol       Date:  2013-04-17       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.